Page last updated: 2024-11-05

tryparsamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

tryparsamide: was MH 1963-92; use TRYPANOCIDAL AGENTS to search TRYPARSAMIDE 1966-92 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID23665572
CHEMBL ID3137699
SCHEMBL ID66153
MeSH IDM0198365

Synonyms (40)

Synonym
sodium 4-arsonophenylglycinamide
n-phenyl glycineamide-p-arsonic acid sodium salt
arsanilic acid, n-(carbamoylmethyl)-, monosodium salt
einecs 209-070-9
tryparsamide [inn]
n-(carbamoylmethyl)arsanilic acid sodium salt
sodium 4-arsonophenylglycineamide
triparsamida [inn-spanish]
tryparsamidum [inn-latin]
arsonic acid, (4-((2-amino-2-oxoethyl)amino)phenyl)-, monosodium salt
ai3-16420
nsc 2050
triparsamide [dcit]
tryparsamide
monosodium n-phenylglycinamide-p-arsonate
triparsamide
554-72-3
tryparsamid
tryparsone
novatoxyl
tryponarsyl
glyphenarsine
sodium 4-(carbamoylmethylamino)benzenearsonate
nsc-2050
sodium n-phenylglycylamide-4-arsonate
trypothane
monosodium n-(carbamoylmethyl)arsanilate
n-(carbamoylmethyl)arsanilic acid, monosodium salt
unii-4nn21hax16
tryparsamidum
4nn21hax16 ,
tryparsamide [usp:inn]
triparsamida
tryparsamide [mi]
tryparsamide [mart.]
SCHEMBL66153
CHEMBL3137699
sodium;[4-[(2-amino-2-oxoethyl)amino]phenyl]-hydroxyarsinate
Q2456821
DTXSID301046341
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (19)

Assay IDTitleYearJournalArticle
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-199027 (96.43)18.7374
1990's0 (0.00)18.2507
2000's1 (3.57)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.33%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (96.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]